the DBL report

Issue #99, November 2017

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on September 21, 2017. The Committee reviewed Manufacturer submissions for twenty-two (22) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of four (4) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, twenty-three (23) Drug Products underwent Expedited Review for listing on the *ADBL* effective October 1, 2017, and one (1) Drug Product underwent Expedited Review for listing on the *ADBL* effective November 1, 2017.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.html

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* via Special Authorization for adjunctive therapy to levodopa for the treatment of patients with advanced stage Parkinson's disease, effective October 1, 2017:

- **NEUPRO*** (rotigotine) (UCB) **2 mg/24 hour, 4 mg/24 hour, 6 mg/24 hour & 8 mg/24 hour transdermal patches**

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL*, effective October 1, 2017:

- **BASAGLAR** (insulin glargine) (LIL) **100 unit/mL injection cartridge & Kwikpen**

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (11/2017)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* via Step Therapy/ Special Authorization for the treatment of Type 2 diabetes (with criteria), effective October 1, 2017:

- **XIGDUO*** (dapagliflozin propanediol monohydrate/ metformin hydrochloride) (AZC) **5 mg/850 mg & 5 mg/1000 mg tablets**

Highlights of Line Extension Drug Products Added

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* via Step Therapy/ Special Authorization effective October 1, 2017:

- **JADENU*** (deferasirox) (NOV) **90 mg, 180 mg & 360 mg tablets**

Highlights of Expedited Interchangeable (IC) Drug Products Added

Addition of the following Expedited Entry IC Drug Products to the *ADBL* via Restricted Benefit has resulted in the creation of a New IC Grouping, effective October 1, 2017:

- **APO-TENOFOVIR*** (tenofovir disoproxil fumarate) (APX) **300 mg tablet**
- **AURO-TENOFOVIR*** (tenofovir disoproxil fumarate) (AUR) **300 mg tablet**
- **MYLAN-TENOFOVIR*** (tenofovir disoproxil fumarate) (MYP) **300 mg tablet**
- **TEVA-TENOFOVIR*** (tenofovir disoproxil fumarate) (TEV) **300 mg tablet**

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of a New IC Grouping, effective November 1, 2017*:*

- **APO-DOXYLAMINE/B6** (doxylamine succinate/ pyridoxine HCl) (APX) **10 mg/10 mg SR tablet**
- **PMS-DOXYLAMINE-PYRIDOXINE** (doxylamine succinate/ pyridoxine HCl) (PMS) **10 mg/10 mg SR tablet**

Addition of the following Entry IC Drug Product to the *ADBL* via Special Authorization has resulted in the creation of New IC Grouping, effective November 1, 2017*:*

- **TARO-BENZOYL PEROXIDE/ CLINDAMYCIN*** (clindamycin phosphate/ benzoyl peroxide) (TAR) **5%/1% topical gel kit**

Highlights of Other Drug Products Added

The following Drug Product was reviewed as a Resubmission, and has been added to the *ADBL* effective November 1, 2017:

- **APO-TRAVOPROST Z** (travoprost) (APX) **0.004% ophthalmic solution**

Highlights of Changes to Currently Listed Products

Additional indications were added for the following Drug Product effective October 1, 2017:

- **HUMIRA*** (adalimumab) (ABV) **40 mg/0.8 mL injection syringe** for Ulcerative Colitis was reviewed by CDR and the Expert Committee and this indication is now eligible for coverage via Special Authorization.

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (11/2017)